Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech : Malaysia approves Sinovac's COVID-19 vaccine for ages 12 to 17

10/01/2021 | 12:13am EST

KUALA LUMPUR, Oct 1 (Reuters) - Malaysia has given conditional approval for a COVID-19 vaccine made by China's Sinovac to be used on young people aged between 12 and 17, its health ministry said on Friday.

Teenagers younger than 18 began receiving COVID-19 doses last month, after vaccinations of more than 80% of adults were completed in one of Southeast Asia's fastest vaccine rollouts that has covered 62% of a population of 32 million.

In a statement, the health ministry said Malaysia's drugs regulator advised priority for Sinovac's product among teenagers without co-morbidities or allergy problems, or otherwise deemed unsuitable for the Pfizer-BioNTech vaccine.

In July, Malaysia said it would stop https://www.reuters.com/world/asia-pacific/malaysia-stop-using-sinovac-vaccine-after-supply-ends-minister-2021-07-15 giving the Sinovac shot when supplies ran out, as it had enough of other vaccines for the national campaign.

Malaysia has continued to receive additional shipments, however. This week, the foreign ministry said China had agreed to donate a million doses of the Sinovac vaccine, following a donation of 500,000 in July. (Reporting by Rozanna Latiff; Editing by Clarence Fernandez)


© Reuters 2021
All news about SINOVAC BIOTECH LTD.
11/23Mexico eyes COVID-19 vaccine booster shots, especially for older adults
RE
11/20Hong Kong authorises Sinovac vaccine for children aged 3-17
RE
11/10Preliminary Results Show SINOVAC's COVID-19 Vaccine Demonstrates Good Safety Profile Am..
PU
11/09Preliminary Results Show SINOVAC's COVID-19 Vaccine Demonstrates Good Safety Profile Am..
BU
11/09Sinovac Biotech Ltd. Announces New Preliminary Data on its Inactivated COVID-19 Vaccine..
CI
11/08UK to add China's Sinovac, India's Covaxin to approved vaccine list
RE
11/03Indian home-grown COVID-19 shot wins WHO emergency use approval
RE
11/03Indian home-grown COVID-19 shot wins WHO emergency use approval
RE
11/03Hong Kong to launch COVID-19 booster campaign from next week
RE
10/30China's Xi calls for COVID-19 vaccine mutual recognition
RE
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,5%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | SVA | AGP8696W1045 | MarketScreener
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED8.34%99 574
WUXI BIOLOGICS (CAYMAN) INC.3.31%57 915
SAMSUNG BIOLOGICS CO.,LTD.7.63%48 998
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-3.72%34 683